The Role of Urotensin II in the Development and Management of Congestive Heart Failure

William Noiles (Editor)
Adel Giaid (Editor)
McGill University Health Centre, Montreal, Quebec, Canada

Series: Cardiology Research and Clinical Developments
BISAC: MED010000

Clear

$0.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Browse Wishlist
Browse Wishlist

Details

Urotensin II (UII) has been shown to cause an endothelium dependant vascular response which has been linked to hypertension and atherosclerosis. It is believed that UII acts on receptors on the intact endothelium to release NO and other vasoactive molecules to cause dilation. In individuals with a damaged endothelium it appears that UII acts directly on VSMC to cause increased contraction via the PKC pathway. More recently UII has been implicated in congestive heart failure, playing a role in cardiac contraction, hypertrophy and collagen deposition. Initial studies in animal models show that the use of UII-antagonists ameliorate the negative responses that occur following damage to the heart, further implicating UII as an important mediator of cardiac change and potential therapeutic target. (Imprint: Nova Biomedical)

ABSTRACT

INTRODUCTION

RECEPTOR ANTAGONISTS

SUMMARY

CONCLUSION

ACKNOWLEDGMENT

REFERENCES

INDEX

You have not viewed any product yet.